| In Vitro |
Most native cells express a variety of different calcium channels and as a result, Ziconotide acetate only partially reduces high-voltage-activated calcium currents in differentiated human neuroblastoma IMR32 cells, rat superior cervical ganglion neurons, and rat hippocampal neurons. Ziconotide acetate also reduces calcium currents that result from expression of the α1B subunit in HEK cells, tsa-201 cells, and Xenopus laevis oocytes[1]. Ziconotide acetate delivers its antinociceptive efficacy by reducing the release of pronociceptive neurotransmitters in the dorsal horn of the spinal cord, thereby inhibiting pain signal transmission[1].
|
| In Vivo |
Ziconotide (i.t.; 25-100 pmol/site; 5 μL; on the 4 th, 10 th, 15 th, 20 th, and 24 th days) acetate reduces the levels of IL-1β and IL-23 in the CNS, as well as IL-17 production in the spleen, 25 days after MOG35-55-elicited EAE, in the mouse model of experimental autoimmune encephalomyelitis (EAE)[2]. Animal Model: Female C57BL/6mice (18-22 g, 6-8 weeks old) injected with myelin oligodendrocytes glycoprotein[2] Dosage: 25 pmol/site, 50 pmol/site, 100 pmol/site Administration: Intrathecal injection; on the 4 th, 10 th, 15 th, 20 th, and 24 th days Result: Significantly reduced the mechanical hypersensitivity in animals with EAE.
|
